{"product_id":"mgnx-five-forces","title":"(MGNX) MacroGenics, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis MacroGenics, Inc. Porter's Five Forces Analysis helps you assess the company’s competitive pressure, industry attractiveness, and key risks. This page already shows a real preview of the actual report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized biologics inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc. relies on a narrow pool of GMP-qualified vendors for cell lines, antibodies, and conjugation inputs, so switching suppliers is slow and risky. In 2025, this kind of biologics sourcing still meant long lead times, strict release testing, and little room for substitution. That gives approved suppliers real leverage on price, capacity, and delivery timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited qualified CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc. likely leans on contract manufacturers for clinical and commercial biologics, so supplier power is high. Capacity at experienced CMOs is tight for complex antibody and ADC programs, and switching can take months because of tech transfer, validation, and comparability work. That raises cost, delay, and quality risk if a provider slips or becomes unavailable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical trial and assay vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics relies on specialized assay, biomarker, and CRO vendors to run its 2025-2026 oncology trials, so a delay can slow readouts, trigger milestone slips, and weaken partner trust. Bargaining power rises when a vendor controls niche biomarker panels or proprietary test platforms, because switching can take months and add cost. That makes supplier risk a real input to trial timing and deal execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDependence on licensed technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics, Inc. faces moderate to high supplier power because its DART and antibody programs can depend on third-party tools, reagents, and licensed know-how. If external IP is needed, licensors can demand higher fees, milestones, or royalties, which matters most in early-stage oncology where more assets are still preclinical or Phase 1.\u003c\/p\u003e\n\u003cp\u003eThis dependence can raise program costs, slow transfers, and make partner terms harder to reset. One clean read: the more a target relies on outside technology, the less pricing power MacroGenics, Inc. has.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed IP can mean royalties.\u003c\/li\u003e\n\u003cli\u003eThird-party tools can lift COGS.\u003c\/li\u003e\n\u003cli\u003eEarly oncology assets are most exposed.\u003c\/li\u003e\n\u003cli\u003ePartner terms can limit flexibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic partner leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics’ partnerships with Incyte, Zai Lab, I-Mab, and Janssen raise supplier power because these large partners can fund development, shape trial pace, and control commercialization rights. Janssen’s parent, Johnson \u0026amp; Johnson, reported $88.8 billion of 2024 sales, while Incyte reported $4.3 billion, so MacroGenics has less bargaining power on economics and terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner funding can steer program timing.\u003c\/li\u003e\n\u003cli\u003eLarge pharma can demand better deal terms.\u003c\/li\u003e\n\u003cli\u003eRights splits can cap upside for MacroGenics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Faces Strong Supplier Leverage in Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc. faces high supplier power because its oncology biologics depend on scarce GMP vendors, CMOs, and niche assay\/CRO providers. Switching is slow and costly due to tech transfer, validation, and comparability work, so approved suppliers can push on price and timing. Large partners also tilt terms, with Johnson \u0026amp; Johnson reporting $88.8 billion of 2024 sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier driver\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP inputs\u003c\/td\u003e\n\u003ctd\u003eLimited substitutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO capacity\u003c\/td\u003e\n\u003ctd\u003eHigh switching cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner scale\u003c\/td\u003e\n\u003ctd\u003eWeaker leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses MacroGenics, Inc.’s competitive pressures, supplier and buyer power, entry barriers, and substitute threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly see MacroGenics’ competitive pressure in one clear view, so you can make smarter biotech decisions faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for MacroGenics, Inc. key claims, helping users verify assumptions fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePowerful payers and insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc. faces strong buyer power because insurers, PBMs, and government payers can block access through prior authorization and tight formularies. In oncology, that pressure is harsher: U.S. Medicare Part D now caps patient out-of-pocket drug spending at $2,000 in 2025, pushing more cost scrutiny onto payers and manufacturers. That makes pricing and reimbursement central to MacroGenics, Inc. commercial uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologists drive adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescribing oncologists have high bargaining power because they decide whether MARGENZA and future products get used, and they can switch fast if another therapy shows better survival, safety, or easier dosing. In metastatic HER2-positive breast cancer, choices are driven by evidence and guideline support, so each new data readout can shift adoption quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and infusion centers can pressure MacroGenics, Inc. on price and access because many cancer drugs are bought through large GPOs and 340B systems, where even a 1% rebate can matter on high-cost therapies. In the U.S., oncology infusions often run through hospital outpatient departments and academic centers, so easy dosing and lower chair time can win faster adoption. If a product needs complex prep or monitoring, demand can drop.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients have limited direct power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients have limited direct power because oncology drug choice is driven more by physicians and payers than by price. In 2025, cancer still caused about 10 million deaths worldwide, so demand is steady, but patients can still sway use through side-effect tolerance and a clear bias for lower-toxicity options.\u003c\/p\u003e\n\u003cp\u003eTheir bargaining power is indirect for MacroGenics, Inc., yet it can still move uptake and payer policy. Patient advocacy has helped shape access rules, and in U.S. oncology, most drug cost is negotiated through insurers, not by patients at the point of sale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow direct price power\u003c\/li\u003e\n\u003cli\u003eHigher influence via adherence\u003c\/li\u003e\n\u003cli\u003eAdvocacy can shift reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner customers are sophisticated\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner customers are sophisticated, so MacroGenics, Inc. faces strong buyer power when it out-licenses assets. Large biopharma partners can push hard on milestones, royalties, and control of development rights, and they often have internal pipelines that give them real alternatives. That cuts MacroGenics, Inc.’s leverage in deal talks, especially when one agreement can involve $100 million-plus in milestones and double-digit royalties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge partners know pricing well\u003c\/li\u003e\n\u003cli\u003eInternal alternatives weaken leverage\u003c\/li\u003e\n\u003cli\u003eMilestones and royalties get squeezed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Faces Strong Buyer Power in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics, Inc. faces strong buyer power because payers, doctors, hospitals, and partners can all push on price, access, and trial terms. In 2025, Medicare Part D capped out-of-pocket drug costs at $2,000, which raised payer scrutiny, while oncology still caused about 10 million deaths worldwide, keeping demand steady but price-sensitive. Partner deals also tilt power toward large biopharma buyers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003cth\u003eKey 2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e$2,000 cap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003e10M deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eMilestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eMacroGenics, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact MacroGenics, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no mockups. The document is fully written and formatted, so what you see here is the final file ready for immediate use. Once your payment is complete, you’ll get instant access to this same analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded oncology landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics faces fierce rivalry because it operates in a packed oncology field where many biopharma firms chase HER2, B7-H3, CD123, and PD-1 targets at the same time. That crowding makes it harder to enroll trial patients, stand out in clinical data, and win physician attention. In oncology, fast readouts and clear efficacy signals can quickly shift market share and investor focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge pharma competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharma keeps pressure high because it can fund more late-stage oncology bets, pay for bigger trials, and back them with global sales teams. In 2025, firms like Merck and Bristol Myers Squibb each spent over $10 billion on R\u0026amp;D, a scale MacroGenics cannot match. That gap hurts MacroGenics in partnering talks and also makes market access tougher once a product reaches launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-data driven competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics competes in a trial-by-trial market: a Phase 2 or Phase 3 readout with higher response rates, better tolerability, or longer durability can reset investor and physician views fast. In oncology, even a 5-10 point efficacy edge can matter, so rivalry is intense and milestone-driven. One weak safety signal or a better rival dataset can shift momentum in a single quarter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline overlap risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics faces high pipeline overlap risk because several of its programs chase crowded targets, so rivals can compete head-to-head or at the same class level. If a similar drug wins approval first in 2025\/2026, MacroGenics can lose pricing power and see slower uptake, especially in markets where payers already favor the first mover.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShared targets raise direct competition.\u003c\/li\u003e\n\u003cli\u003eFirst approval can shape payer access.\u003c\/li\u003e\n\u003cli\u003eLate entrants often need discounting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics competes in a partnership race, where biotech value is set not just by drugs but by licensing, co-development, and regional rights. Stronger peers can tie up capital and partners first, which can leave MacroGenics with fewer options for late-stage funding and commercialization. \u003c\/p\u003e\n\u003cp\u003eIn 2024, biotech dealmaking stayed selective, so partner quality mattered as much as price. That raises the stakes for MacroGenics: if rivals secure the best alliances, they can speed trials and share risk while MacroGenics may need to accept weaker terms. \u003c\/p\u003e\n\u003cp\u003eThis rivalry is especially sharp in oncology, where platform access and BD execution can shape who gets first shot at top-tier partners. For MacroGenics, every missed deal can mean slower development, less cash support, and less reach in key markets. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeals matter as much as drugs.\u003c\/li\u003e\n\u003cli\u003ePeers can lock up key partners.\u003c\/li\u003e\n\u003cli\u003eBetter alliances cut funding risk.\u003c\/li\u003e\n\u003cli\u003eWeak terms can slow market reach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Faces Fierce Oncology Rivalry and Big Pharma Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because MacroGenics competes in crowded oncology targets, where trial data, safety, and first approval can quickly swing share. Big pharma intensifies pressure: in 2025, Merck and Bristol Myers Squibb each spent over $10 billion on R\u0026amp;D, far above MacroGenics. Partner access and launch timing also shape who wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePeer\u003c\/th\u003e\n\u003cth\u003e2025 R\u0026amp;D\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck\u003c\/td\u003e\n\u003ctd\u003e$10B+\u003c\/td\u003e\n\u003ctd\u003eFunds bigger oncology trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBristol Myers Squibb\u003c\/td\u003e\n\u003ctd\u003e$10B+\u003c\/td\u003e\n\u003ctd\u003eRaises rivalry and deal pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative cancer modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and physicians can choose chemotherapy, radiation, surgery, or other targeted drugs instead of MacroGenics, Inc. assets. With about 20 million new cancer cases worldwide in 2022, treatment choice often shifts by stage and biomarker status, so substitutes stay relevant across many indications. That keeps the threat of substitutes meaningful, especially when a standard therapy offers similar outcomes at lower cost or wider access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompeting immunotherapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCheckpoint inhibitors, CAR-T, ADCs, and bispecific antibodies can replace some MacroGenics, Inc. pipeline assets, especially where rivals show better response rates or easier dosing. By 2025, the FDA had cleared more than a dozen ADCs, and bispecifics were moving into key oncology standards, raising the bar for older programs. If one rival modality becomes standard of care, substitution pressure can rise fast and cut MacroGenics, Inc. pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard-of-care regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMARGENZA faces strong substitute risk because HER2 care still follows entrenched regimens like trastuzumab, pertuzumab, T-DM1, and T-DXd. In SOPHIA, MARGENZA’s median PFS was 5.8 months versus 4.9 months for chemotherapy, so doctors may stay with better-known pathways when outcomes are similar or safety is more familiar. That makes switching costly and slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-drug innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-drug options can squeeze MacroGenics, Inc.'s market. Better diagnostics and biomarker selection can keep only a smaller, tighter patient group on drug therapy, while surgery, radiation, or other local care can replace systemic agents in some cancers.\u003c\/p\u003e\n\u003cp\u003eThe result is a narrower addressable market, especially as precision oncology pushes treatment toward earlier, less drug-heavy care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiagnostics can cut eligible patients.\u003c\/li\u003e\n\u003cli\u003eLocal care can replace systemic drugs.\u003c\/li\u003e\n\u003cli\u003eBiomarkers narrow the treated pool.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline cannibalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics, Inc. faces internal substitution risk because its pipeline can cannibalize older assets if newer programs target the same biology or indication. That can pull capital, trial slots, and sales focus toward the stronger candidate, which may shrink the long-term role of MARGENZA, the company’s first approved product.\u003c\/p\u003e\n\u003cp\u003eIn practice, this is a portfolio risk, not a market-share loss to rivals. If one asset shows better efficacy or safety in late-stage data, management can reallocate spend fast, so substitute pressure inside MacroGenics, Inc. can be higher than external pressure.\u003c\/p\u003e\n\u003cp\u003eFor investors, the key watchpoint is whether newer programs expand the label or replace legacy revenue instead of adding it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInternal overlap can dilute MARGENZA\u003c\/li\u003e\n\u003cli\u003eBest data gets funding first\u003c\/li\u003e\n\u003cli\u003ePipeline choices can shift value fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Faces High Substitute Risk in Cancer Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for MacroGenics, Inc. because cancer care can shift to surgery, radiation, chemo, or rival biologics. With 20 million new cancer cases in 2022, treatment choice stays broad, so pricing power can be weak. In SOPHIA, MARGENZA’s median PFS was 5.8 months vs 4.9 months for chemo, so close efficacy lifts swap risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal new cancer cases\u003c\/td\u003e\n\u003ctd\u003e20 million, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMARGENZA PFS\u003c\/td\u003e\n\u003ctd\u003e5.8 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemo PFS\u003c\/td\u003e\n\u003ctd\u003e4.9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh scientific barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeveloping antibody-based oncology drugs needs deep science, specialized teams, and long trials, so new rivals face a high bar. MacroGenics, Inc. works in a field where biologics development can take 7-10 years and cost well over $1B, while only 8 oncology drugs were FDA-approved in 2024. Most entrants cannot build and validate complex antibodies fast enough, which keeps entry risk low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and capital intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical development is capital heavy: a single biotech program can burn tens of millions of dollars in Phase 2 and Phase 3 alone, before any sales start. It also needs deep FDA\/EMA know-how, GMP manufacturing, and 7-12 years of runway, so weak entrants usually run out of cash first. That makes the threat of new entrants low for MacroGenics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eADC and bispecific programs need tight process control, and the FDA had approved only about 15 ADCs by 2025, which shows how hard this space is to scale. New entrants must build reliable cell-culture, linker-payload, and QC systems before they can produce clinical-grade material. That gives MacroGenics, Inc. a real edge because established biologics infrastructure cuts scale-up risk and time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics, Inc. and its partners build on proprietary platforms and target-specific intellectual property, so patent strength is a real barrier to new entrants. Strong claims can block or delay copycat programs, while a challenger must either license rights or steer clear of protected targets. That lifts entry costs and makes fast follow-on competition harder in 2025-2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents raise entry costs.\u003c\/li\u003e\n\u003cli\u003eLicensing can be mandatory.\u003c\/li\u003e\n\u003cli\u003eProtected targets narrow rivals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech startups still emerge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech startups still enter oncology, even with steep regulatory, clinical, and capital needs. In 2025, venture money kept funding platform bets and niche targets, so new challengers can move fast when a thesis looks strong. For MacroGenics, Inc., that keeps the threat real, just moderated by high failure rates and long trial timelines.\u003c\/p\u003e\n\u003cp\u003eOne line: barriers slow entrants, but they do not stop them.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVenture capital can fund fast entry\u003c\/li\u003e\n\u003cli\u003eNiche targets lower launch costs\u003c\/li\u003e\n\u003cli\u003eOncology still attracts new startups\u003c\/li\u003e\n\u003cli\u003eBarriers reduce, not erase, risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Entry Threat Keeps MacroGenics Protected\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for MacroGenics, Inc. stays low because antibody oncology needs long trials, heavy cash, and hard-to-build manufacturing. Only 8 oncology drugs won FDA approval in 2024, and ADCs were still only about 15 FDA-approved by 2025, so scale is scarce. Still, venture-backed startups can enter niche targets, so the barrier blocks most rivals but not all.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA oncology approvals\u003c\/td\u003e\n\u003ctd\u003e8 in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved ADCs\u003c\/td\u003e\n\u003ctd\u003eAbout 15 by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntry barrier\u003c\/td\u003e\n\u003ctd\u003eHigh capital, long timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234595840265,"sku":"mgnx-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mgnx-five-forces.webp?v=1785724980","url":"https:\/\/dcfanalyst.com\/products\/mgnx-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}